Metabolomics identifies metabolite markers in plasma and extracellular vesicles within plasma in patients with asthma

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2024-10-19 DOI:10.1016/j.cca.2024.120010

Chih-Jung Chang , Qi-Wen Ma , Tian-Lin Li , Jun-An Liu , Cheng-Hsien Hsieh , Liang Chen

{"title":"Metabolomics identifies metabolite markers in plasma and extracellular vesicles within plasma in patients with asthma","authors":"Chih-Jung Chang , Qi-Wen Ma , Tian-Lin Li , Jun-An Liu , Cheng-Hsien Hsieh , Liang Chen","doi":"10.1016/j.cca.2024.120010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Plasma and extracellular vesicles (EVs) derived from plasma are important sources of information regarding individual health. Metabolomic analysis of plasma and EVs may provide new methods for predicting disease occurrence. This study aims to analyze the metabolomic characteristics of plasma and plasma EVs in asthma patients.</div></div><div><h3>Methods</h3><div>Plasma samples were collected from healthy individuals and asthma patients. EVs were isolated from the plasma using ultracentrifugation. The isolated EVs were characterized by nanoparticle tracking analysis and flow cytometry. Metabolomic analysis was performed using a liquid chromatography-mass spectrometry platform.</div></div><div><h3>Results</h3><div>This study successfully extracted EVs from plasma samples. Metabolomic analysis revealed that the composition of differential metabolites in the plasma and EVs of asthma patients was similar. KEGG pathway analysis indicated that the number of upregulated metabolic pathways enriched with differential metabolites in the plasma EVs of asthma patients was significantly greater than that in the plasma samples. Pathways associated with the onset of asthma included asthma, systemic lupus erythematosus, glycerophospholipid metabolism, and autophagy – other, primarily involving the following five metabolites: PS(18:1(9Z)/18:2(9Z,12Z)), PC(18:1(9Z)e/2:0), PS(24:1(15Z)/22:2(13Z,16Z)), PE(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)), and PE(16:0/20:3(8Z,11Z,14Z)). Receiver operating characteristic analysis results suggested that these five differential metabolites may serve as potential biomarkers for asthma.</div></div><div><h3>Conclusion</h3><div>We identified the metabolic characteristics of plasma and EVs in asthma patients, confirming that the metabolites in plasma EVs may serve as potential biomarkers for asthma. This finding not only enhances our understanding of the pathogenesis of asthma but also opens new avenues for targeted therapy.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"565 ","pages":"Article 120010"},"PeriodicalIF":3.2000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898124022630","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Plasma and extracellular vesicles (EVs) derived from plasma are important sources of information regarding individual health. Metabolomic analysis of plasma and EVs may provide new methods for predicting disease occurrence. This study aims to analyze the metabolomic characteristics of plasma and plasma EVs in asthma patients.

Methods

Plasma samples were collected from healthy individuals and asthma patients. EVs were isolated from the plasma using ultracentrifugation. The isolated EVs were characterized by nanoparticle tracking analysis and flow cytometry. Metabolomic analysis was performed using a liquid chromatography-mass spectrometry platform.

Results

This study successfully extracted EVs from plasma samples. Metabolomic analysis revealed that the composition of differential metabolites in the plasma and EVs of asthma patients was similar. KEGG pathway analysis indicated that the number of upregulated metabolic pathways enriched with differential metabolites in the plasma EVs of asthma patients was significantly greater than that in the plasma samples. Pathways associated with the onset of asthma included asthma, systemic lupus erythematosus, glycerophospholipid metabolism, and autophagy – other, primarily involving the following five metabolites: PS(18:1(9Z)/18:2(9Z,12Z)), PC(18:1(9Z)e/2:0), PS(24:1(15Z)/22:2(13Z,16Z)), PE(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)), and PE(16:0/20:3(8Z,11Z,14Z)). Receiver operating characteristic analysis results suggested that these five differential metabolites may serve as potential biomarkers for asthma.

Conclusion

We identified the metabolic characteristics of plasma and EVs in asthma patients, confirming that the metabolites in plasma EVs may serve as potential biomarkers for asthma. This finding not only enhances our understanding of the pathogenesis of asthma but also opens new avenues for targeted therapy.

查看原文本刊更多论文

代谢组学确定了哮喘患者血浆和血浆内细胞外囊泡中的代谢标记物。

背景：血浆和来自血浆的细胞外囊泡（EVs）是个人健康信息的重要来源。对血浆和细胞外囊泡进行代谢组学分析可为预测疾病的发生提供新的方法。本研究旨在分析哮喘患者血浆和血浆EVs的代谢组学特征：方法：收集健康人和哮喘患者的血浆样本。方法：采集健康人和哮喘患者的血浆样本，采用超速离心法从血浆中分离出 EVs。通过纳米粒子追踪分析和流式细胞术对分离出的 EVs 进行表征。使用液相色谱-质谱平台进行了代谢组学分析：结果：这项研究成功地从血浆样本中提取了 EVs。代谢组学分析表明，哮喘患者血浆和 EVs 中差异代谢物的组成相似。KEGG通路分析表明，哮喘患者血浆EVs中富含差异代谢物的上调代谢通路数量明显多于血浆样本。与哮喘发病相关的途径包括哮喘、系统性红斑狼疮、甘油磷脂代谢和自噬--其他，主要涉及以下五种代谢物：PS(18:1(9Z)/18:2(9Z,12Z)), PC(18:1(9Z)e/2:0), PS(24:1(15Z)/22:2(13Z,16Z)), PE(22:4(7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z)), and PE(16:0/20:3(8Z,11Z,14Z)).接收器操作特征分析结果表明，这五种不同的代谢物可作为哮喘的潜在生物标志物：我们确定了哮喘患者血浆和 EVs 的代谢特征，证实血浆 EVs 中的代谢物可作为哮喘的潜在生物标志物。这一发现不仅加深了我们对哮喘发病机制的了解，还为靶向治疗开辟了新途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.